Fast PCR on any real-time cycler
10 September, 2007 | Supplied by: QIAGEN Pty Ltd
QuantiFast Kits are claimed to deliver faster results in real-time PCR. With time savings of up to 60% on existing cyclers claimed, there is no need for hardware upgrades. In addition, no PCR optimisation is required, even if using previously established assays. Kits are available for SYBR Green or probe-based detection in PCR, two-step RT-PCR and one-step RT-PCR.
Could bacterial infections be altering our DNA?
03 September, 2007
Scientists have discovered the genome of a bacterial parasite incorporated into the genome of its host species, according to a report published recently in Science.
Scientists uncover DNA repair mechanism
23 August, 2007
Scientists at the American Johns Hopkins University have now uncovered the mechanism the body uses to identify and remove errors in the genetic code, according to the prestigious scientific journal Nature.
Brain gene flicks the switch on gender
21 August, 2007
University of Adelaide researchers have discovered a way of creating a male mouse without a Y chromosome by manipulating a single gene in the developing foetus.
Development of a rapid diagnostic test for Hand, Foot and Mouth Disease
14 August, 2007
Singaporean academics and industry have joined together to develop a rapid test for Hand, Foot and Mouth Disease (HFMD).
Who owns your DNA?
06 August, 2007 by Kylie Wilson-Field, Journalist
There is no doubt that genetic testing and the mapping of the human genome has changed the face of medicine, but it also raises new debates over ethics and, more importantly, who owns your genetic information?
Vial filling system for clinical trials
06 August, 2007 | Supplied by: Nupac Industries Pty Ltd
Bosch Pharmaceutical has augmented its portfolio of vial filling solutions with the FLT1020, a system designed for increased efficiency in clinical trials. The filler is a downsized alternative to larger vial filling systems, specifically designed for the clinical/trials phase. Based on production technology, the FLT1020 minimises packaging and processing variables when shifting into the full scale production stage. Pharmaceutical firms moving from clinical trials to the production phase need to be able to predict how a drug will handle on the filling line and the FLT1020 addresses the demands of pharmaceutical manufacturers that require a scaled down unit that replicates the conditions of mass production. A smaller system enables firms to anticipate potential variables, streamline validation procedures and thus minimise the risks associated with scale up.
DNA fragment cloning
06 August, 2007 | Supplied by: Life Technologies
MultiSite Gateway Pro Technology enables users to efficiently and conveniently assemble multiple DNA fragments in the desired order and orientation into a Gateway Expression vector.
Three is better than two but not than four
23 July, 2007
Three-stage procedures offer an optimal relationship between costs and benefits in analysing genetic influences in diseases and therapies, a fact that has major practical importance for the ever growing number of gene analyses.
Eucalyptus tapped as the next tree genome to be sequenced
12 July, 2007
An ambitious international effort has been launched to decode the genome of Eucalyptus, one of the world's most valuable fibre- and paper-producing trees - with the goal to maximise its potential in the burgeoning bio energy market and for capturing excess atmospheric carbon.
Technical notes
06 July, 2007 | Supplied by: Scientifix Pty Ltd
Scientifix has released the latest edition of Clontechniques.
Introducing Personal Automation
06 July, 2007 | Supplied by: Promega Pty Ltd
The Maxwell 16 System offers automated and truly walk-away nucleic acid purification that saves time and labour by eliminating reagent preparation, pipetting and centrifugation steps.
Possible population screening for FXS
05 July, 2007
An automated test could enable population screening to identify carriers of the genetic disease fragile X syndrome (FXS), the most common inherited form of mental retardation, reports a study in the April issue of Genetics in Medicine, published by the American College of Medical Genetics and Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
Genomic test to predict who needs chemotherapy
04 July, 2007
Duke University Medical Center scientists have developed a genomic test to predict which patients with early-stage lung cancer will need chemotherapy to live and which patients can avoid the toxic regimen of drugs.
DNA-damage test could aid drug development
28 June, 2007
Researchers from Massachusetts Institute of Technology and Whitehead Institute have developed a cell culture test for assessing a compound’s genetic toxicity that may prove dramatically cheaper than existing animal tests. This assay would allow genetic toxicity to be examined far earlier in the drug development process.
